366
Views
49
CrossRef citations to date
0
Altmetric
Research Article

Sustained release docetaxel-incorporated lipid nanoparticles with improved pharmacokinetics for oral and parenteral administration

, , , , , , , , , & show all
Pages 250-261 | Received 21 Dec 2016, Accepted 29 May 2017, Published online: 15 Jun 2017

References

  • Abdelbary G, Fahmy RH. Diazepam-loaded solid lipid nanoparticles: Design and characterization. AAPS PharmSciTech, 2009;10:211–9.
  • Almeida EDP, Costa AA, Serafini MR, Rossetti FC, Marchetti JM, Sarmento VHV, Nunes RS, Valerio MEG, Araújo AAS, Lira AAM. Preparation and characterization of chloroaluminum phthalocyanine-loaded solid lipid nanoparticles by thermal analysis and powder X-ray diffraction techniques. J Therm Anal Calorim, 2011;108:191–6.
  • Anton N, Benoit J-P, Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates—A review. J Control Release, 2008;128:185–99.
  • Choi JY, Thapa RK, Yong CS, Kim JO. Nanoparticle-based combination drug delivery systems for synergistic cancer treatment. J Pharm Investig, 2016;46:325–39.
  • Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: Physical and biopharmaceutical aspects. Pharm Res, 1995;12:1561–72.
  • Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release, 2010;148:135–46.
  • Estella-Hermoso De Mendoza A, Rayo M, Mollinedo F, Blanco-Prieto MJ. Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: Development and in vitro characterization. Eur J Pharm Biopharm, 2008;68:207–13.
  • Fang G, Tang B, Chao Y, Zhang Y, Xu H, Tang X. Improved oral bioavailability of docetaxel by nanostructured lipid carriers: In vitro characteristics, in vivo evaluation and intestinal transport studies. RSC Adv, 2015;5:96437–47.
  • Gao K, Sun J, Liu K, Liu X, He Z. Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel. Drug Dev Ind Pharm, 2008;34:1227–37.
  • Harde H, Das M, Jain S. Solid lipid nanoparticles: An oral bioavailability enhancer vehicle. Expert Opin Drug Deliv, 2011;8:1407–24.
  • Hu K, Cao S, Hu F, Feng J. Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: Preparation, in vitro, and in vivo evaluation. Int J Nanomedicine, 2012;7:3537–45.
  • Jain A, Thakur K, Kush P, Jain UK. Docetaxel loaded chitosan nanoparticles: Formulation, characterization and cytotoxicity studies. Int J Biol Macromol, 2014;69:546–53.
  • Jianping Q, Yi L, Wei W. Absorption, disposition and pharmacokinetics of solid lipid nanoparticles. Curr Drug Metab, 2012;13:418–28.
  • Joshi MD, Muller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm, 2009;71:161–72.
  • Jun YJ, Jadhav VB, Min JH, Cui JX, Chae SW, Choi JM, Kim I-S, Choi S-J, Lee HJ, Sohn YS. Stable and efficient delivery of docetaxel by micelle-encapsulation using a tripodal cyclotriphosphazene amphiphile. Int J Pharm, 2012;422:374–80.
  • Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems – An overview. Acta Pharm Sin B, 2013;3:361–72.
  • Kanapathipillai M, Brock A, Ingber DE. Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment. Adv Drug Deliv Rev, 2014;79-80:107–18.
  • Kim J-K, Yuan H, Nie J, Yang Y-T, Leggas M, Potter PM, Rinehart J, Jay M, Lu X. High payload dual therapeutic-imaging nanocarriers for triggered tumor delivery. Small, 2012;8:2895–903.
  • Kolate A, Baradia D, Patil S, Vhora I, Kore G, Misra A. PEG - A versatile conjugating ligand for drugs and drug delivery systems. J Control Release, 2014;192:67–81.
  • Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release, 2004;99:259–69.
  • Le Garrec D, Gori S, Karkan D, Luo L, Lessard DG, Smith D, Ranger M, Yessine MA, Leroux JC. Preparation, characterization, cytotoxicity and biodistribution of docetaxel-loaded polymeric micelle formulations. J Drug Deliv Sci Technol, 2005;15:115–20.
  • Lim S-J, Kim C-K. Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int J Pharm, 2002;243:135–46.
  • Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces, 2011;85:262–9.
  • Lu X, Howard MD, Talbert DR, Rinehart JJ, Potter PM, Jay M, Leggas M. Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants II: role of plasma esterases in drug release. AAPS J, 2009;11:120–2.
  • Luan J, Yang X, Chu L, Xi Y, Zhai G. PEGylated long circulating nanostructured lipid carriers for Amoitone B: Preparation, cytotoxicity and intracellular uptake. J Colloid Interface Sci, 2014;428:49–56.
  • Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev, 2001;47:165–96.
  • Mei L, Zhang Z, Zhao L, Huang L, Yang XL, Tang J, Feng SS. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Deliv Rev, 2013;65:880–90.
  • Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: Formulating poorly water-soluble compounds. Toxicol Pathol, 2008;36:43–8.
  • Mosallaei N, Jaafari MR, Hanafi-Bojd MY, Golmohammadzadeh S, Malaekeh-Nikouei B. Docetaxel-loaded solid lipid nanoparticles: Preparation, characterization, in vitro, and in vivo evaluations. J Pharm Sci, 2013;102:1994–2004.
  • Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – A review of the state of the art. Eur J Pharm Biopharm, 2000;50:161–77.
  • Naguib YW, Rodriguez BL, Li X, Hursting SD, Williams RO III, Cui Z. Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: In vitro and in vivo evaluation. Mol Pharm, 2014;11:1239–49.
  • Narvekar M, Xue HY, Eoh JY, Wong HL. Nanocarrier for poorly water-soluble anticancer drugs–barriers of translation and solutions. AAPS PharmSciTech, 2014;15:822–33.
  • Natarajan JV, Nugraha C, Ng XW, Venkatraman S. Sustained-release from nanocarriers: A review. J Control Release, 2014;193:122–38.
  • Park JY, Kim M-G, Shim G, Oh Y-K. Lipid-based antigen delivery systems. J Pharm Investig, 2016;46:295–304.
  • Park O, Yu G, Jung H, Mok H. Recent studies on micro-/nano-sized biomaterials for cancer immunotherapy. J Pharm Investig, 2017;47:11–18.
  • Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol, 2007;2:751–60.
  • Puri A, Loomis K, Smith B, Lee J-H, Yavlovich A, Heldman E, Blumenthal R. Lipid-based nanoparticles as pharmaceutical drug carriers: From concepts to clinic. Crit Rev Ther Drug Carrier Syst, 2009;26:523–80.
  • Qureshi OS, Zeb A, Akram M, Kim M-S, Kang J-H, Kim H-S, Majid A, Han I, Chang S-Y, Bae O-N, Kim J-K. Enhanced acute anti-inflammatory effects of CORM-2-loaded nanoparticles via sustained carbon monoxide delivery. Eur J Pharm Biopharm, 2016;108:187–95.
  • Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization. J Microencapsul, 1999;16:205–13.
  • Seo YG, Kim DH, Ramasamy T, Kim JH, Marasini N, Oh YK, Kim DW, Kim JK, Yong CS, Kim JO, Choi HG. Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect. Int J Pharm, 2013;452:412–20.
  • Severino P, Andreani T, Macedo AS, Fangueiro JF, Santana MH, Silva AM, Souto EB. Current state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J Drug Deliv, 2012;2012:750891.
  • Silvia F, Eugenia N, Shyam B, Sharath H, Melissa L, Alessandro G. Docetaxel/2-hydroxypropyl β-cyclodextrin inclusion complex increases docetaxel solubility and release from a nanochannel drug delivery system. Curr Drug Targets, 2015;16:1645–9.
  • Sim T, Lim C, Hoang NH, Joo H, Lee JW, Kim D-W, Lee ES, Youn YS, Kim JO, Oh KT. Nanomedicines for oral administration based on diverse nanoplatform. J Pharm Investig, 2016;46:351–62.
  • Singh SK, Banala VT, Gupta GK, Verma A, Shukla R, Pawar VK, Tripathi P, Mishra PR. Development of docetaxel nanocapsules for improving in vitro cytotoxicity and cellular uptake in MCF-7 cells. Drug Dev Ind Pharm, 2015;41:1759–68.
  • Üner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC): Their benefits as colloidal drug carrier systems. Pharmazie, 2006;61:375–86.
  • Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine, 2007;2:289–300.
  • Wissing S, Kayser O, Müller R. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev, 2004;56:1257–72.
  • Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev, 2007;59:491–504.
  • Yin YM, Cui FD, Mu CF, Choi MK, Kim JS, Chung SJ, Shim CK, Kim DD. Docetaxel microemulsion for enhanced oral bioavailability: Preparation and in vitro and in vivo evaluation. J Control Release, 2009;140:86–94.
  • Yousaf AM, Mustapha O, Kim DW, Kim DS, Kim KS, Jin SG, Yong CS, Youn YS, Oh YK, Kim JO, Choi HG. Novel electrosprayed nanospherules for enhanced aqueous solubility and oral bioavailability of poorly water-soluble fenofibrate. Int J Nanomedicine, 2016;11:213–21.
  • Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics, 2012;2:3–44.
  • Zeb A, Qureshi OS, Kim H-S, Cha J-H, Kim H-S, Kim J-K. Improved skin permeation of methotrexate via nanosized ultradeformable liposomes. Int J Nanomedicine, 2016;11:3813–24.
  • Zhang F, Chang M, Yu Y, Zhang Y, Liu G, Wei T, Zuo T, Guan Y, Lin G, Zhao Z. Preparation and evaluation of lipid emulsified docetaxel-loaded nanoparticles. J Pharm Pharmacol, 2015;67:1546–55.
  • Zhang L, Zhang N. How nanotechnology can enhance docetaxel therapy. Int J Nanomedicine, 2013;8:2927–41.
  • Zhao P, Astruc D. Docetaxel nanotechnology in anticancer therapy. ChemMedChem, 2012;7:952–72.
  • Zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm, 1998;45:149–55.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.